CN102361642A - 用升高的剂量的熊去氧胆酸治疗非酒精性脂肪性肝炎的方法 - Google Patents

用升高的剂量的熊去氧胆酸治疗非酒精性脂肪性肝炎的方法 Download PDF

Info

Publication number
CN102361642A
CN102361642A CN2010800119928A CN201080011992A CN102361642A CN 102361642 A CN102361642 A CN 102361642A CN 2010800119928 A CN2010800119928 A CN 2010800119928A CN 201080011992 A CN201080011992 A CN 201080011992A CN 102361642 A CN102361642 A CN 102361642A
Authority
CN
China
Prior art keywords
udca
patient
treatment
nash
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800119928A
Other languages
English (en)
Chinese (zh)
Inventor
吉恩·斯佩纳德
弗拉德·拉奇
马克·里维埃尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptalis Pharma Canada ULC
Original Assignee
Axcan Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcan Pharma Inc filed Critical Axcan Pharma Inc
Publication of CN102361642A publication Critical patent/CN102361642A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2010800119928A 2009-03-17 2010-03-16 用升高的剂量的熊去氧胆酸治疗非酒精性脂肪性肝炎的方法 Pending CN102361642A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16095509P 2009-03-17 2009-03-17
US61/160,955 2009-03-17
PCT/IB2010/000551 WO2010106420A1 (en) 2009-03-17 2010-03-16 Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid

Publications (1)

Publication Number Publication Date
CN102361642A true CN102361642A (zh) 2012-02-22

Family

ID=42167374

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800119928A Pending CN102361642A (zh) 2009-03-17 2010-03-16 用升高的剂量的熊去氧胆酸治疗非酒精性脂肪性肝炎的方法

Country Status (12)

Country Link
US (1) US20120071451A1 (https=)
EP (1) EP2408457A1 (https=)
JP (1) JP2012520866A (https=)
KR (1) KR20120008034A (https=)
CN (1) CN102361642A (https=)
AU (1) AU2010224587A1 (https=)
CA (1) CA2755708A1 (https=)
IL (1) IL215195A0 (https=)
MX (1) MX2011009757A (https=)
RU (1) RU2011139643A (https=)
WO (1) WO2010106420A1 (https=)
ZA (1) ZA201107578B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110958878A (zh) * 2017-06-21 2020-04-03 诺华股份有限公司 用于治疗非酒精性脂肪性肝炎的licofligozin
CN114245743A (zh) * 2019-07-30 2022-03-25 Ko生物技术有限公司 预防、缓解或治疗肝损伤的组合物和方法
CN115038459A (zh) * 2020-01-28 2022-09-09 希尔帕医疗保健有限公司 熊去氧胆酸的给药方法
CN116782898A (zh) * 2020-10-23 2023-09-19 深圳君圣泰生物技术有限公司 小檗碱熊去氧胆酸盐的组合物及其用于治疗脂肪性肝病、糖尿病和高脂血症的方法
US12274718B2 (en) 2019-07-30 2025-04-15 Kobiolabs, Inc. Composition and method for preventing, alleviating, or treating liver injury

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
KR101401628B1 (ko) * 2012-12-24 2014-06-02 삼성제약공업주식회사 간기능 개선용 정제 및 그 제조 방법
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
SG10201801654RA (en) 2014-05-28 2018-04-27 Childrens Hospital Med Ct Methods and systems for converting precursor cells into gastric tissues through directed differentiation
IL282156B (en) * 2014-07-29 2022-07-01 Shenzhen Hightide Biopharmaceutical Ltd Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
AU2015331848B2 (en) 2014-10-17 2022-03-03 Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
WO2017084234A1 (zh) * 2015-11-19 2017-05-26 欣耀生医股份有限公司 预防或治疗脂肪肝的药物组合物
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
EP4553082A3 (en) 2016-11-04 2025-08-20 Children's Hospital Medical Center Liver organoid compositions and methods of making and using same
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
JP7248586B2 (ja) 2017-04-14 2023-03-29 チルドレンズ ホスピタル メディカル センター 複数ドナー幹細胞組成物およびそれを作製する方法
EP3694603B1 (en) 2017-10-10 2026-04-08 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
KR101887561B1 (ko) * 2017-11-15 2018-09-06 주식회사 대웅제약 간염 바이러스에 의해 유발된 간 섬유화의 개선을 위한 약학 조성물
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
EP4678727A3 (en) 2018-07-26 2026-03-11 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
RU2686042C1 (ru) * 2018-09-04 2019-04-23 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ лечения неалкогольной жировой болезни печени при метаболическом синдроме
CA3112026A1 (en) 2018-09-12 2020-03-19 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
US12600943B2 (en) 2019-02-01 2026-04-14 The University Of Hong Kong Innervated organoid compositions and methods of making same
AU2020283048A1 (en) 2019-05-31 2021-12-23 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
US12497597B2 (en) 2019-05-31 2025-12-16 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
CN115137732A (zh) * 2021-03-29 2022-10-04 中国科学院大连化学物理研究所 Gpr120受体激动剂及熊去氧胆酸的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297229B1 (en) * 1994-11-14 2001-10-02 Mayo Foundation For Medical Education And Research Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297229B1 (en) * 1994-11-14 2001-10-02 Mayo Foundation For Medical Education And Research Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KEITH D. LINDOR 等: "Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis: Results of a Randomized Trial", 《HEPATOLOGY》 *
SUSAN N. CULLEN ET AL: "High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective", 《JOURNAL OF HEPATOLOGY》 *
UNKNOWN: "《ClinicalTrials.gov》", 2 February 2009, HTTP://WWW.CLINICALTRIALS.GOV/CT2/SHOW/NCT00470171?TERM=URSODEOXYCHOLIC&RANK=32> *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110958878A (zh) * 2017-06-21 2020-04-03 诺华股份有限公司 用于治疗非酒精性脂肪性肝炎的licofligozin
CN114245743A (zh) * 2019-07-30 2022-03-25 Ko生物技术有限公司 预防、缓解或治疗肝损伤的组合物和方法
CN114245743B (zh) * 2019-07-30 2023-12-08 Ko生物技术有限公司 预防、缓解或治疗肝损伤的组合物和方法
US12274718B2 (en) 2019-07-30 2025-04-15 Kobiolabs, Inc. Composition and method for preventing, alleviating, or treating liver injury
CN115038459A (zh) * 2020-01-28 2022-09-09 希尔帕医疗保健有限公司 熊去氧胆酸的给药方法
CN116782898A (zh) * 2020-10-23 2023-09-19 深圳君圣泰生物技术有限公司 小檗碱熊去氧胆酸盐的组合物及其用于治疗脂肪性肝病、糖尿病和高脂血症的方法

Also Published As

Publication number Publication date
US20120071451A1 (en) 2012-03-22
EP2408457A1 (en) 2012-01-25
MX2011009757A (es) 2012-02-28
CA2755708A1 (en) 2010-09-23
AU2010224587A1 (en) 2011-09-22
ZA201107578B (en) 2013-06-26
JP2012520866A (ja) 2012-09-10
WO2010106420A1 (en) 2010-09-23
KR20120008034A (ko) 2012-01-25
RU2011139643A (ru) 2013-04-27
IL215195A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
CN102361642A (zh) 用升高的剂量的熊去氧胆酸治疗非酒精性脂肪性肝炎的方法
ES2763137T3 (es) Bifidobacterias para el tratamiento de diabetes y afecciones relacionadas
US20090148545A1 (en) Methods of use and nutritional compositions of touchi extract
CN110150669B (zh) 一种适于糖尿病患者食用的益生菌组合物及其应用
EP3661525B1 (en) Roseburia hominis, eubacterium eligens, and combinations thereof as biotherapeutics
Kurebayashi et al. Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study
US20210393657A1 (en) Synthetic composition for preventing or treating cvd
CN105582028A (zh) 樟芝用于治疗疾病的用途
AU2023307487A1 (en) Combination of bifidobacterium and fucosylated hmo for use in increasing nmn or nad+
CN101420867A (zh) 新颖的营养药物组合物
CN112770749A (zh) 双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用
CN1835762B (zh) 用于治疗和/或预防与2型糖尿病有关的功能障碍和抗胰岛素性的组合物
US20140170128A1 (en) Compositions for the management of glycated hemoglobin and blood glucose
US10179158B2 (en) Composition and method for control of post-prandial glucose
CN100496536C (zh) α-葡萄糖苷酶活性抑制剂
CN103446166A (zh) 肝功能改善剂
JP2022535718A (ja) 非セリアック小麦及び／又はグルテン過敏症を患っている患者の症状の処置において使用するためのヒトミルクオリゴ糖
CA3249631A1 (en) METHODS AND COMPOSITIONS TO SLOW THE DEVELOPMENT OF DIABETES OR REDUCE THE RISK OF DIABETES
Bhat Probiotics in the Management of Diabetes 4
Zainab et al. Role of the gut microbiome in the pathophysiology and treatment of type 2 diabetes mellitus: a mini review
EP4620479A1 (en) Postbiotic preparation comprising pediococcus acidilactici for preventing or treating obesity
CN111032067A (zh) 用于治疗脂肪肝病的刺地榆提取物
YASMIN et al. Effect of honey supplementation on plasma levels of short chain fatty acids in malnurished children
TWI698244B (zh) 小分子褐藻醣膠與藻褐素之組合物用於製備改善非酒精性脂肪肝之組成物的用途
Mohi-Ud-din et al. Probiotics in the Management of Diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Quebec

Applicant after: Aptalis Pharma Canada Inc.

Address before: Quebec

Applicant before: Axcan Pharma, Inc

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: AXCAN PHARMA INC. TO: APTALIS PHARMA CANADA INC.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120222